ClinicalTrials.gg
CompletedNCT01096160Updated Aug 12, 2019Results posted

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

A Phase 1 interventional study of MK-8226 BID, 1 mg and MK-8266 BID, 1.8 mg in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Hypertension by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Hypertension · Merck & Co., Inc.

Enrollment
20th of 32
40 · median 84
Started
2010
with 5 others
Phase 1
17 of 33
none open now
Registered
18th of 33
by date

Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 20th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2010, is one of 17 in phase 1, and was the 18th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 33 studies in Hypertension by Merck & Co., Inc is open now. The open studies under Hypertension, anywhere →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Hypertension by Merck & Co., Inc as a file.
02

Study summary

This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.

Read the detailed description

This study evaluated AEs, discontinuation due to AEs, and effects on hemodynamic parameters, including systolic blood pressure (SBP) and aortic augmentation index (AIx), following multiple oral doses of MK-8266. Five serial panels, each consisting of eight participants (40 participants in Panels A, B, C, D, and E), were randomized to receive either MK-8266 or matching placebo twice daily (BID) or three times daily (TID) for 10 consecutive days. Although the original plan was to evaluate MK-8266 treatment in Panels D and E using both BID and TID regimens, the study actually evaluated identical TID regimens in these panels.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is male with essential hypertension (high blood pressure)
  • Participant is in good general health (with the exception of hypertension)
  • Participant has a (BMI) \<= 33 kg/m\^2 at the Screening visit
  • Participant has a count >= 150,000 cu/mL at the Screening visit
  • Participant has a positive AIx at the Screening visit

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of stroke, chronic seizure, or major neurological disease
  • Participant has a functional disability that can interfere with rising from a seated position to the standing position
  • Participant has any history of a bleeding or clotting disorder
  • Participant has a history of cancer
  • Participant is unable to refrain from or anticipates the use of any prescription or non-prescription medication
  • Participant consumes excessive amounts of alcohol or caffeinated beverages daily
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Panel A: MK-8266 BID, 1 mg/Placebo

    MK-8266 1 mg (0.7 mg in the morning \[AM\] + 0.3 mg in the evening \[PM\]), or as matching placebo BID.

    Drug: MK-8226 BID, 1 mg · Drug: Placebo BID (Panel A)

  • Experimental
    Panel B: MK-8266 BID, 1.8 mg/Placebo

    MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.

    Drug: MK-8266 BID, 1.8 mg · Drug: Placebo BID (Panel B)

  • Experimental
    Panel C: MK-8266 TID, 1.8 mg/Placebo

    MK-8266 TID, 1.8 mg (0.6 mg every 6 hours \[q6hr\]), or as matching placebo TID.

    Drug: MK-8266 TID, 1.8 mg · Drug: Placebo TID (Panel C)

  • Experimental
    Panel D: MK-8266 TID, 2.4 mg/Placebo

    MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.

    Drug: MK-8266 TID, 2.4 mg · Drug: Placebo TID (Panel D)

  • Experimental
    Panel E: MK-8266 TID, 2.4 mg/Placebo

    MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.

    Drug: MK-8266 TID, 2.4 mg · Drug: Placebo TID (Panel E)

Interventions

  • MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

    Also known as: MK-8266

  • MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

    Also known as: MK-8266

  • MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

    Also known as: MK-8266

  • MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.

    Also known as: MK-8266

  • MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.

    Also known as: MK-8266

  • DrugPlacebo BID (Panel A)

    Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

  • DrugPlacebo BID (Panel B)

    Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

  • DrugPlacebo TID (Panel C)

    Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

  • DrugPlacebo TID (Panel D)

    Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.

  • DrugPlacebo TID (Panel E)

    Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.

06

What researchers measure

Primary outcomes

  1. Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up

    Assessment of the number of participants with at least one clinical or laboratory AE in those receiving multiple oral doses of MK-8266. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.

    Time frame: Up to 24 days

  2. Participants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE

    Assessment of the number of participants receiving MK-8266 who discontinued therapy due to an AE over 10 days of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. The number of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Days 0-10.

    Time frame: Up to 10 days

  3. Change From Baseline in Systolic Blood Pressure (SBP) Following Multiple Oral Doses of MK-8266 or Placebo

    Assessment of the change from baseline in SBP, obtained using a validated, semi-automated oscillometric device. Evaluated for MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis.

    Time frame: Baseline and Day 10

  4. Heart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo

    Assessment of HR (beats/min) on Day 10 (24-hours postdose) with MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs). Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis. Baseline HR values are shown in the Baseline Characteristics section for Panels A, B, C, D, E.

    Time frame: Day 10 (24 hours postdose)

Secondary outcomes

  1. Aortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo

    Assessment of the central, ascending aortic blood pressure augmentation index (AIx), based on measurement of central pulse pressure at selected time points on Day 10, as measured by applanation tonometry of the radial artery. This outcome measure assessed the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.

    Time frame: Day 10

  2. Change From Baseline in Cyclic Guanosine Monophosphate (cGMP) Following Multiple Oral Doses of MK-8266 or Placebo

    Assessment of whole blood samples for cGMP analysis, based on samples obtained predose as well as 4 and 24 hours postdose on Day 1 and Day 10, and predose only on Day 4. The change from baseline in cGMP was assessed at 24 hours postdose on Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.

    Time frame: Baseline and Day 10

  3. Percent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo

    The percent inhibition of ADP-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of ADP (2.5 µM) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10 only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.

    Time frame: Baseline and Day 10 (5 hours postdose)

  4. Percent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo

    The percent inhibition of collagen-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of collagen (2 µg/mL) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10, only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.

    Time frame: Baseline and Day 10 (5 hours postdose)

07

Results

Posted Aug 12, 2019

Participant flow

Participant flow — Overall Study
MilestonePanel A: MK-8266 BID (1 mg)Panel A: Placebo BIDPanel B: MK-8266 BID (1.8 mg)Panel B: Placebo BIDPanel C: MK-8266 TID (1.8 mg)Panel C: Placebo TIDPanel D: MK-8266 TID (2.4 mg)Panel D: Placebo TIDPanel E: MK-8266 TID (2.4 mg)Panel E: Placebo TID
Started6262626262
Completed6252524241
Not completed0010102021
Withdrew: Adverse event0010000001
Withdrew: Met stopping criteria per protocol0000102020

Outcome measures

PrimaryParticipants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up

Assessment of the number of participants with at least one clinical or laboratory AE in those receiving multiple oral doses of MK-8266. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product.

Time frame:
Up to 24 days
Reported as:
Number · Count of Participants
Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up
Count of ParticipantsPanel A: MK-8266 BID (1 mg)Panel A: PlaceboPanel B: MK-8266 BID (1.8 mg)Panel B: PlaceboPanel C: MK-8266 TID (1.8 mg)Panel C: PlaceboPanel D: MK-8266 TID (2.4 mg)Panel D: PlaceboPanel E: MK-8266 TID (2.4 mg)Panel E: Placebo
Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE) During Treatment and Postdose Follow-up5051314152
PrimaryParticipants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE

Assessment of the number of participants receiving MK-8266 who discontinued therapy due to an AE over 10 days of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. The number of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Days 0-10.

Time frame:
Up to 10 days
Reported as:
Number · Count of Participants
Participants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE
Count of ParticipantsPanel A: MK-8266 BID (1 mg)Panel A: PlaceboPanel B: MK-8266 BID (1.8 mg)Panel B: PlaceboPanel C: MK-8266 TID, 1.8 mgPanel C: PlaceboPanel D: MK-8266 TID (2.4 mg)Panel D: PlaceboPanel E: MK-8266 2.4 mg TIDPanel E: Placebo
Participants Receiving MK-8266 or Placebo Who Discontinued Treatment Due to an AE0010000001
PrimaryChange From Baseline in Systolic Blood Pressure (SBP) Following Multiple Oral Doses of MK-8266 or Placebo

Assessment of the change from baseline in SBP, obtained using a validated, semi-automated oscillometric device. Evaluated for MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis.

Time frame:
Baseline and Day 10
Reported as:
Least squares mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) Following Multiple Oral Doses of MK-8266 or Placebo
Millimeters of mercury (mmHg)Panel A: MK-8266 BID, 1 mgPanel B: MK-8266 BID, 1.8 mgPanel C: MK-8266 TID, 1.8 mgPanels D & E Combined: MK-8266 TID, 2.4 mgPooled Placebo
Baseline value141.5 ± 8.96132.6 ± 6.66148.6 ± 23.77134.5 ± 8.98146.7 ± 12.07
Change from Baseline at Day 10-5.09 ± 7.04-2.18 ± 6.80-4.78 ± 7.640.77 ± 6.62-3.18 ± 7.72
Statistical analysis
  • Panel A: MK-8266 BID, 1 mg vs Pooled Placebo · Linear mixed effects model · p = 0.1194 · Mean difference (final values): -7.08 · 90% CI -17.1 to 2.92
  • Panel B: MK-8266 BID, 1.8 mg vs Pooled Placebo · Linear mixed effects model · p = 0.0224 · Mean difference (final values): -13.1 · 90% CI -23.7 to -2.48
  • Panel C: MK-8266 TID, 1.8 mg vs Pooled Placebo · Linear mixed effects model · p = 0.4791 · Mean difference (final values): 0.33 · 90% CI -10.3 to 10.91
  • Panels D & E Combined: MK-8266 TID, 2.4 mg vs Pooled Placebo · Linear mixed effcts model · p = 0.0705 · Mean difference (final values): -8.21 · 90% CI -17.4 to 1.01
PrimaryHeart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo

Assessment of HR (beats/min) on Day 10 (24-hours postdose) with MK-8266 relative to placebo in participants, as measured by the time weighted average change over 24 hours postdose (TWA\^0-24hrs). Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this analysis. Baseline HR values are shown in the Baseline Characteristics section for Panels A, B, C, D, E.

Time frame:
Day 10 (24 hours postdose)
Reported as:
Mean · Beats per minute
Heart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo
Beats per minutePanel A: MK-8266 BID (1 mg)Panel B: MK-8266 BID (1.8 mg)Panel C: MK-8266 TID (1.8 mg)Panels D & E Combined: MK-8266 TID: MK-8266 TID (2.4 mg)Pooled Placebo
Heart Rate (HR) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo65.89 ± 5.5969.32 ± 7.8762.30 ± 5.2866.10 ± 5.3862.04 ± 5.98
Statistical analysis
  • Panel A: MK-8266 BID (1 mg) vs Pooled Placebo · Linear mixed effects model · p = 0.1161 · Mean difference (final values): 3.85 · 90% CI -1.51 to 9.22
  • Panel B: MK-8266 BID (1.8 mg) vs Pooled Placebo · Linear mixed effects model · p = 0.0189 · Mean difference (final values): 7.28 · 90% CI 1.60 to 12.97
  • Panel C: MK-8266 TID (1.8 mg) vs Pooled Placebo · Linear mixed effects model · p = 0.4689 · Mean difference (final values): 0.26 · 90% CI -5.42 to 5.95
  • Panels D & E Combined: MK-8266 TID: MK-8266 TID (2.4 mg) vs Pooled Placebo · Linear mixed effects model · p = 0.0869 · Mean difference (final values): 4.06 · 90% CI -0.89 to 9.01
SecondaryAortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo

Assessment of the central, ascending aortic blood pressure augmentation index (AIx), based on measurement of central pulse pressure at selected time points on Day 10, as measured by applanation tonometry of the radial artery. This outcome measure assessed the time weighted average change over 24 hours postdose (TWA\^0-24hrs) on dosing Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.

Time frame:
Day 10
Reported as:
Least squares mean · mmHg
Aortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo
mmHgPanel A: MK-8266 BID, 1 mgPanel B: MK-8266 BID, 1.8 mgPanel C: MK-8266 TID, 1.8 mgPanels D & E Combined: MK-8266 TID, 2.4 mgPooled Placebo
Aortic Augmentation Index (AIx) on Day 10 Following Multiple Oral Doses of MK-8266 or Placebo8.81 ± 4.867.45 ± 2.5913.50 ± 8.9511.89 ± 7.0018.68 ± 6.68
Statistical analysis
  • Panel A: MK-8266 BID, 1 mg vs Pooled Placebo · Linear mixed effects model · p = 0.003 · Mean difference (final values): -9.87 · 90% CI -15.7 to -4.09
  • Panel B: MK-8266 BID, 1.8 mg vs Pooled Placebo · Linear mixed effects model · p = 0.002 · Mean difference (final values): -11.2 · 90% CI -17.3 to -5.10
  • Panel C: MK-8266 TID, 1.8 mg vs Pooled Placebo · Linear mixed effcts model · p = 0.080 · Mean difference (final values): -5.18 · 90% CI -11.3 to 0.95
  • Panels D & E Combined: MK-8266 TID, 2.4 mg vs Pooled Placebo · Linear mixed effcts model · p = 0.019 · Mean difference (final values): -6.79 · 90% CI -12.1 to -1.46
SecondaryChange From Baseline in Cyclic Guanosine Monophosphate (cGMP) Following Multiple Oral Doses of MK-8266 or Placebo

Assessment of whole blood samples for cGMP analysis, based on samples obtained predose as well as 4 and 24 hours postdose on Day 1 and Day 10, and predose only on Day 4. The change from baseline in cGMP was assessed at 24 hours postdose on Day 10. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this assessment.

Time frame:
Baseline and Day 10
Reported as:
Least squares mean · nanomoles (nM)
Change From Baseline in Cyclic Guanosine Monophosphate (cGMP) Following Multiple Oral Doses of MK-8266 or Placebo
nanomoles (nM)Panel A: MK-8266 BID, 1 mgPanel B: MK-8266 BID, 1.8 mgPanel C: MK-8266 TID, 1.8 mgPanels D & E Combined: MK-8266 TID, 2.4 mgPooled Placebo
Baseline value1.61 ± 0.770.74 ± 0.501.69 ± 1.152.68 ± 1.290.54 ± 0.21
Change from Baseline at Day 101.34 ± 2.741.74 ± 4.620.43 ± 0.660.81 ± 2.781.05 ± 1.16
Statistical analysis
  • Panel A: MK-8266 BID, 1 mg vs Pooled Placebo · Linear mixed effects model · p = 0.318 · Geometric mean ratio: 1.28 · 90% CI 0.53 to 3.05
  • Panel B: MK-8266 BID, 1.8 mg vs Pooled Placebo · Linear mixed effects model · p = 0.17 · Geometric mean ratio: 1.66 · 90% CI 0.66 to 4.17
  • Panel C: MK-8266 TID, 1.8 mg vs Pooled Placebo · Linear mixed effcts model · p = 0.054 · Geometric mean ratio: 0.41 · 90% CI 0.16 to 1.02
  • Panels D & E Combined: MK-8266 TID, 2.4 mg vs Pooled Placebo · Linear mixed effcts model · p = 0.297 · Geometric mean ratio: 0.78 · 90% CI 0.35 to 1.73
SecondaryPercent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo

The percent inhibition of ADP-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of ADP (2.5 µM) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10 only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.

Time frame:
Baseline and Day 10 (5 hours postdose)
Reported as:
Mean · Percent inhibition
Percent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo
Percent inhibitionPanels D & E Combined: MK-8266 TID (2.4 mg)Placebo
Percent Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate (ADP) Following Multiple Oral Doses of MK-8266 or Placebo-12.3 ± 29.81-12.4 ± 18.89
SecondaryPercent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo

The percent inhibition of collagen-induced platelet aggregation from Baseline to 5 hours postdose on Day 10 was assessed and is summarized here. Platelet aggregation was initiated by addition of collagen (2 µg/mL) to the participant's blood sample. Aggregation was followed for 5 minutes after addition of the agonist, and the maximum percent of light transmission (extent of aggregation) obtained during this period, as well as the instrument-calculated slope (rate of aggregation), were reported. Post treatment platelet aggregation is expressed as a percent of each participant's pretreatment level of aggregation. Panel D and Panel E had identical treatments (MK-8266 0.8 mg TID), which were combined for this summary. The data are very limited. On Day 10, only 8 participants received MK-8266 0.8 mg TID and 3 participants received placebo.

Time frame:
Baseline and Day 10 (5 hours postdose)
Reported as:
Mean · Percent inhibition
Percent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo
Percent inhibitionPanels D & E Combined: MK-8266 TID (2.4 mg)Placebo
Percent Inhibition of Platelet Aggregation Induced by Collagen Following Multiple Oral Doses of MK-8266 or Placebo-17.7 ± 26.30-8.87 ± 33.76

Adverse events

Collected over 11 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panel A: MK-8266 BID, 1 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel A: Placebo BID0/2 (0%)0/2 (0%)0/2 (0%)
Panel B: MK-8266 BID, 1.8 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel B: Placebo BID0/2 (0%)0/2 (0%)1/2 (50%)
Panel C: MK-8266 TID, 1.8 mg0/6 (0%)0/6 (0%)3/6 (50%)
Panel C: Placebo TID0/2 (0%)0/2 (0%)1/2 (50%)
Panel D: MK-8266 TID, 2.4 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Panel D: Placebo TID0/2 (0%)0/2 (0%)1/2 (50%)
Panel E: MK-8266 TID, 2.4 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Panel E: Placebo TID0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPanel A: MK-8266 BID, 1 mgPanel A: Placebo BIDPanel B: MK-8266 BID, 1.8 mgPanel B: Placebo BIDPanel C: MK-8266 TID, 1.8 mgPanel C: Placebo TIDPanel D: MK-8266 TID, 2.4 mgPanel D: Placebo TIDPanel E: MK-8266 TID, 2.4 mgPanel E: Placebo TID
HeadacheNervous system disorders2/60/24/61/23/61/22/61/24/61/2
Abdominal painGastrointestinal disorders0/60/20/60/20/61/20/60/20/60/2
DiarrhoeaGastrointestinal disorders0/60/20/60/20/61/20/60/20/60/2
NauseaGastrointestinal disorders0/60/21/61/20/60/20/61/21/60/2
PruritusSkin and subcutaneous tissue disorders1/60/21/60/20/61/20/60/20/60/2
HypertensionVascular disorders0/60/21/60/20/60/20/60/20/61/2
Abnormal sensation in eyeEye disorders0/60/22/60/20/60/20/60/20/60/2
Supraventricular tachycardiaCardiac disorders1/60/20/60/20/60/20/60/20/60/2
Ventricular tachycardiaCardiac disorders1/60/20/60/20/60/20/60/20/60/2
Ear painEar and labyrinth disorders1/60/20/60/20/60/20/60/20/60/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panel A: MK-8266 BID, 1 mgPanel A: Placebo BIDPanel B: MK-8266 BID, 1.8 mgPanel B: Placebo BIDPanel C: MK-8266 TID, 1.8 mgPanel C: Placebo TIDPanel D: MK-8266 TID, 2.4 mgPanel D: Placebo TIDPanel E: MK-8266 TID, 2.4 mgPanel E: Placebo TIDTotal
Mean49.2 ± 1.547.5 ± 4.945.5 ± 7.852.0 ± 1.446.5 ± 3.454.0 ± 1.446.2 ± 5.546.5 ± 7.847.2 ± 5.248.5 ± 0.747.6 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)Panel A: MK-8266 BID, 1 mgPanel A: Placebo BIDPanel B: MK-8266 BID, 1.8 mgPanel B: Placebo BIDPanel C: MK-8266 TID, 1.8 mgPanel C: Placebo TIDPanel D: MK-8266 TID, 2.4 mgPanel D: Placebo TIDPanel E: MK-8266 TID, 2.4 mgPanel E: Placebo TIDTotal
Female00000000000
Male626262626240
Baseline HR
Baseline HR(Beats per minute)Panel A: MK-8266 BID, 1 mgPanel A: Placebo BIDPanel B: MK-8266 BID, 1.8 mgPanel B: Placebo BIDPanel C: MK-8266 TID, 1.8 mgPanel C: Placebo TIDPanel D: MK-8266 TID, 2.4 mgPanel D: Placebo TIDPanel E: MK-8266 TID, 2.4 mgPanel E: Placebo TIDTotal
Median70 (53 to 91)90 (71 to 108)79 (71 to 92)89 (79 to 99)74 (43 to 85)69 (65 to 72)72 (59 to 84)88 (79 to 96)74 (60 to 127)81 (67 to 94)73 (43 to 127)
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2010 to primary completion in Nov 2010, 8 months.

Results were first posted in Aug 2019, 8 years 9 months after primary completion.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 8 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2010
First posted
Mar 30, 2010
StartActual
Mar 1, 2010
Primary completionActual
Nov 1, 2010
CompletionActual
Nov 1, 2010
Results first posted
Aug 12, 2019
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01096160
Responsible party
Sponsor
First posted
Mar 30, 2010
Start date
Mar 1, 2010
Primary completion
Nov 1, 2010
Completion
Nov 1, 2010
Results posted
Aug 12, 2019
Last update
Aug 12, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Solrikitug · MK-8266

Start the discussion